Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 222Colorectal Neoplasms 196Rectal Neoplasms 174Stomach Neoplasms 116Pancreatic Neoplasms 100Neoplasm Metastasis 77Colonic Neoplasms 59Neoplasms 50Esophageal Neoplasms 39Triple Negative Breast Neoplasms 38Nasopharyngeal Carcinoma 28Biliary Tract Neoplasms 27Cholangiocarcinoma 23Gallbladder Neoplasms 21Locally Advanced Rectal Cancer 17Carcinoma, Hepatocellular 17Adenocarcinoma 15Gastrointestinal Neoplasms 13Colorectal Cancer Metastatic 13Head and Neck Neoplasms 12Bile Duct Neoplasms 12Adenocarcinoma Of Esophagus 12Esophageal Squamous Cell Carcinoma 11Breast Neoplasms, Male 11Brain Neoplasms 11Liver Neoplasms 10Carcinoma, Renal Cell 10Neuroendocrine Tumors 9Unspecified Adult Solid Tumor, Protocol Specific 8Squamous Cell Carcinoma of Head and Neck 8

Interventions

Everolimus 5Temozolomide 4sargramostim 2montanide ISA 51 2lutetium Lu 177 dotatate 2incomplete Freund's adjuvant 2Sunitinib 2Specimen Handling 2Sorafenib 2Octreotide 2Magnetic Resonance Spectroscopy 2Leucovorin 2Fluorouracil 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1nimotuzumab 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1cabozantinib 1atezolizumab 1abemaciclib 1Wound Healing 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenoma, Islet Cell × Capecitabine × Clear all
NCT05247905 2025-04-02

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
31 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡